The clinical trial, HA-1 TCR-T Cell Therapy is a phase 1 trial. HA-1 is a protein made only in blood and blood-forming cells, including normal blood cells and leukemia. HA-1 comes in two forms — one form is 'visible" to the immune system and the other is not. If you meet the eligibility criteria, we might be able to offer you a new type of cell therapy if the leukemia or related blood disorder has relapsed after transplant.
Below you will find the eligibility survey. If you pass the survey, you will have the option of being contacted by the researchers who are running this trial to discuss if you wish to enroll.
Dr. Krakow works to develop safe and effective cellular immunotherapy approaches for patients with leukemia and lymphomas, especially those who have relapsed after blood and marrow transplantation.